2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Neoplasms, Nerve Tissue
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Neoplasm Metastasis
1
Liver Neoplasms
1
Fibrosis
1
Colon Cancer Liver Metastasis
1
Carcinoma, Pancreatic Ductal
1
Ascites
1
Abdominal Neoplasms
1
Abdominal Injuries
1
Interventions
Gemcitabine
15
130-nm albumin-bound paclitaxel
10
Albumin-Bound Paclitaxel
7
Oxaliplatin
5
Paclitaxel
4
Leucovorin
4
Fluorouracil
4
Carboplatin
4
Cisplatin
3
Cetuximab
3
Bevacizumab
3
pembrolizumab
2
napabucasin
2
Pemetrexed
2
PEGPH20
2
MK-4721
2
Irinotecan
2
tremelimumab
1
selinexor
1
relacorilant
1
ponatinib
1
neratinib
1
irinotecan sucrosofate
1
folfirinox
1
ensituximab
1
durvalumab
1
contrast agent BR1
1
cobimetinib
1
ceritinib
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Pancreatic Ductal
×
contrast agent BR1
×
Clear all
NCT04146441
2023-01-19
PDAC
St. Olavs Hospital
Phase 2
Completed
20 enrolled